Microbix Biosystems (TSX:MBX) reported that revenue rose 84% to almost $2-million for the first quarter ended Dec. 31, 2016, from $1.1-million a year earlier.Read More
Avivagen (TSX-V:VIV), with the help of the National Research Council of Canada (NRC), will undertake a project to establish proof of concept for a first human health application of its OxC-beta technology.Read More
Avivagen (TSX-V:VIV) has made the first industrial-scale sale of its OxC-beta livestock to UNAHCO in the Philippines.
The sale is for 150 kilograms of OxC-beta livestock 10% premix at pricing in line with Avivagen's target. The order will supplement approximately 7.5 million kilograms of UNAHCO-branded commercial feed, an amount sufficient for about three million broiler chickens or 350,000 piglets.Read More
Avivagen (TSX-V:VIV) has agreed to supply OxC-beta Livestock to UNAHCO for sales and distribution in the Republic of the Philippines.
OxC-beta has been shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. Comprised of fully-oxidized beta-carotene, OxC-beta is a non-antibiotic means of maintaining optimal health and growth in livestock animals such as swine and poultry.Read More
Avivagen (TSX-V:VIV) and UNAHCO have registered OxC-beta Livestock as an imported livestock feed additive, authorizing its use in all species in the Philippines.
UNAHCO is a feed and veterinary unit of Unilab, the largest pharmaceutical company in the Philippines. UNAHCO provides a broad range of animal healthcare and nutrition products and programs to meet the requirements of both large commercial and smaller individual farmers in the Philippines as well as abroad.Read More
Avivagen (TSX-V:VIV) has provided results of four new trials of OxC-beta livestock as a feed additive for swine in the Philippines and Vietnam, and broiler poultry in the Philippines and Spain.
In a new trial with the National Institute of Animal Sciences for Vietnam, the use of OxC-beta significantly improved the major commercial parameters of average daily gain (ADG), final body weight (FBW), feed conversion ratio (FCR) and rates of diarrhea and mortality, compared with non-supplemented animals.Read More
Avivagen (TSX-V:VIV) plans to collaborate with the Jintai group of companies for a joint venture to commercialize OxC-beta Livestock in China.
The companies plan to create a Sino-Canadian joint venture company based in Xi’an, Shaanxi province, to register and commercialize OxC-beta Livestock, initially for use in poultry and swine.Read More
Avivagen (TSX-V:VIV) has reported positive results of a trial of OxC-beta Livestock as a feed additive for swine run by COFCO Nutrition and Health Research Institute (COFCO NHRI) of Beijing.
The trial evaluated OxC-beta’s effect on growth efficiency and health of pigs raised under local conditions during the post-weaning “starter” period. OxC-beta enhanced growth in the “starter” pigs in this trial, a result consistent with previously-reported trials in swine and broiler poultry.Read More
Avivagen (TSX-V:VIV) has started a trial with UNAHCO at the University of the Philippines Los Banos to measure the benefits of OxC-beta livestock as a feed additive for broiler poultry.
Trial design reflects a collaboration between Avivagen and UNAHCO and it will measure the benefits of OxC-beta on the performance and welfare of broiler poultry raised under typical local commercial production conditions for their full growth cycle.Read More
In a letter to shareholders, Cameron Groome, CEO of Avivagen (TSX-V:VIV), provided and update about the company and its business plans.
Mr. Groome said Avivagen continues the process of commercializing its non-antibiotic and naturally-occurring products, based on OxC-beta technology that, among their uses, are showing efficacy as a replacement for antibiotics in helping to maintain optimal health and growth in livestock.Read More